Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Angiotensin-converting-enzyme inhibitors provide renal protection in patients with mild-to-moderate renal insufficiency (serum creatinine level, 3.0 mg per deciliter or less). We assessed the efficacy and safety of benazepril in patients without diabetes who had advanced renal insufficiency. METHODS: We enrolled 422 patients in a randomized, double-blind study. After an eight-week run-in period, 104 patients with serum creatinine levels of 1.5 to 3.0 mg per deciliter (group 1) received 20 mg of benazepril per day, whereas 224 patients with serum creatinine levels of 3.1 to 5.0 mg per deciliter (group 2) were randomly assigned to receive 20 mg of benazepril per day (112 patients) or placebo (112 patients) and then followed for a mean of 3.4 years. All patients received conventional antihypertensive therapy. The primary outcome was the composite of a doubling of the serum creatinine level, end-stage renal disease, or death. Secondary end points included changes in the level of proteinuria and the rate of progression of renal disease. RESULTS: Of 102 patients in group 1, 22 (22 percent) reached the primary end point, as compared with 44 of 108 patients given benazepril in group 2 (41 percent) and 65 of 107 patients given placebo in group 2 (60 percent). As compared with placebo, benazepril was associated with a 43 percent reduction in the risk of the primary end point in group 2 (P=0.005). This benefit did not appear to be attributable to blood-pressure control. Benazepril therapy was associated with a 52 percent reduction in the level of proteinuria and a reduction of 23 percent in the rate of decline in renal function. The overall incidence of major adverse events in the benazepril and placebo subgroups of group 2 was similar. CONCLUSIONS: Benazepril conferred substantial renal benefits in patients without diabetes who had advanced renal insufficiency. (ClinicalTrials.gov number, NCT00270426.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Our trial confirms that the kidneyprotective effects of SGLT2 inhibitors extend to the broader population of persons with chronic kidney disease without type 2 diabetes, for whom ACE inhibitors are the only pharmacologic treatments that have been shown to prevent kidney failure.3,4”
From Dapagliflozin in Patients with Chronic Kidney Disease (2020) · cites this paper as [4]
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
(2000) · Journal of the American Society of Nephrology · Cited by 1,718
Peterson, J. C., Adler, S., Burkart, J. M., Greene, T., Hebert, L. A., Hunsicker, L. G., King, A. J., Klahr, S., Massry, S. G., Seifter, J. L., et al. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-123-10-199511150-00003 · Cited by 1,342
Bakris, G. L., & Weir, M. R. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.5.685 · Cited by 823
Coresh, J., Astor, B. C., McQuillan, G., Kusek, J., Greene, T., Van Lente, F., & Levey, A. S. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32765 · Cited by 717
A SIMPLE METHOD OF ESTIMATING PROGRESSION OF CHRONIC RENAL FAILURE
Mitch, W. E., Walser, M., Buffington, G. A., & Lemann, J. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91974-7 · Cited by 459
Ruggenenti, P., Nefrologia”(GISEN), O. B. O. T. “. I. D. S. E. I., Perna, A., Mosconi, L., Pisoni, R., & Remuzzi, G. (1998) · Kidney International · doi:10.1046/j.1523-1755.1998.00874.x · Cited by 434
Research works printed but not linked: 4
- 2001, Chin J Nephrol, 17, 77
- Hou FF, 2005, Zhonghua Yi Xue Za Zhi, 85, 458
- Zhang GH, 2005, Zhonghua Nei Ke Za Zhi, 44, 592
- Levey AS, 2000, J Am Soc Nephrol, 11, 155A
Cited by
Items 401–500 of 702
Renin-Angiotensin Inhibition and Outcomes in HFrEF and Advanced Kidney Disease
Patel, S. S., Lam, P. H., Kanonidis, E. I., Ahmed, A. A., Raman, V. K., Wu, W., Rossignol, P., Arundel, C., Faselis, C. J., Kanonidis, I. E., et al. (2023) · The American Journal of Medicine · doi:10.1016/j.amjmed.2023.03.017 · Cited by 9
Speedtsberg, E. S., & Tepel, M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1281107 · Cited by 9
Retarding the progression of chronic kidney disease with renin angiotensin system blockade
Annigeri, R., Limesh, M., Mk, M., Kowdle, P. C., Rao, B., Balasubramanian, S., & Seshadri, R. (2012) · Indian Journal of Nephrology · doi:10.4103/0971-4065.97126 · Cited by 9
“[12,16] However, their efficacy above and beyond the antihypertensive effect in the progression of nonproteinuric CKD is not established.”
BackgroundUpdate on the management of chronic kidney disease.
Rivera, J. A., O’Hare, A. M., & Harper, G. M. (2012) · PubMed · Cited by 14
A Stepped Care Approach to the Management of Chronic Kidney Disease
Fogarty, D. G., & Taal, M. W. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4160-6193-9.10061-2 · Cited by 9
McCullough, P. A., & Rangaswami, J. (2017) · The Nephron journals/Nephron journals · doi:10.1159/000485645 · Cited by 9
Mandal, M., Pradhan, R., Lourderaj, U., & Balamurugan, R. (2023) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.2c02668 · Cited by 9
Direct Renin Inhibitor: Aliskiren in Chronic Kidney Disease
Morishita, Y., & Kusano, E. (2012) · Nephro-Urology Monthly · doi:10.5812/numonthly.3679 · Cited by 9
“Many clinical trials have demonstrated that blockade of RAAS by ACEIs or ARBs could prevent the development and progression of CKD and its complications such as HT and CVD (9-14).”
Trinkley, K. E., Nikels, S. M., Page, R. L., II, & Joy, M. S. (2014) · International Journal of General Medicine · doi:10.2147/ijgm.s61795 · Cited by 9
Benazepril slows progression of renal dysfunction in patients with non‐diabetic renal disease
Ishimitsu, T., Akashiba, A., Kameda, T., Takahashi, T., Ohta, S., Yoshii, M., Minami, J., Ono, H., Numabe, A., & Matsuoka, H. (2007) · Nephrology · doi:10.1111/j.1440-1797.2007.00786.x · Cited by 9
“In a previous study of 281 Chinese patients, four patients discontinued benazepril therapy secondary to hyperkalemia.(10) Thus, hyperkalemia does not seem a major obstacle to the long-term ACE inhibitor therapy in patients with non-diabetic renal insufficiency.”
BackgroundResultBorrelli, S., Nicola, L. D., Conte, G., & Minutolo, R. (2018) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-319-59918-2_21 · Cited by 9
Tamura, Y., Kosuga, M., Yamashita, M., Tomioka, S., Sasaki, M., Hikita, T., Nakajima, H., Kojima, K., & Uchida, S. (2008) · Clinical and Experimental Nephrology · doi:10.1007/s10157-008-0040-y · Cited by 9
“Hou et al. [ 11 ] studied 224 hypertensive patients who were placed in two groups: the benazepril group with BP 153/ 87 mmHg and the placebo group with BP 152/85 mmHg.”
BackgroundResultInfluentialAn update on proteinuric chronic kidney disease: The dual-goal approach
HIRSCH, S. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.10.705 · Cited by 11
Williams, M. S., Levine, G. N., Kalra, D. K., Agarwala, A., Baptiste, D., Cigarroa, J. E., Diekemper, R. L., Foster, M., Gulati, M., Henry, T. D., et al. (2025) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/hcq.0000000000000140 · Cited by 12
Moore, H. J., Wu, W., Heidenreich, P. A., Rossignol, P., Patel, S. S., Lu, F., Lam, P. H., Ahmed, A. A., Faselis, C. J., Butler, J., et al. (2025) · The American Journal of Medicine · doi:10.1016/j.amjmed.2025.05.024 · Cited by 8
Rouette, J., Yin, H., McDonald, E. G., Barkun, A. N., & Azoulay, L. (2021) · Drug Safety · doi:10.1007/s40264-021-01128-1 · Cited by 12
Li, Y., Jiang, S., Gao, H., Yang, Y., Liu, X., & Li, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1004289 · Cited by 8
“New components of the RAS have been identified recently, including angiotensin (Ang)-(1-7), Mas receptor (MasR), Ang-(1-9) and alamandine (6, 7).”
BackgroundInfluentialDeterminants of urgent start dialysis in a chronic kidney disease cohort followed by nephrologists
Tachikart, A., Vachey, C., Vauchy, C., Savet, C., Ducloux, D., & Courivaud, C. (2023) · BMC Nephrology · doi:10.1186/s12882-023-03222-1 · Cited by 8
Sheng, X.-X., Qiu, C.-Y., Wang, L., Du, Y.-J., Tang, L., Chen, J., Liu, G., Yang, S., Zheng, P., & Chen, M. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202402402 · Cited by 8
Jiang, Z., Zhu, X., Jiang, H., Zhao, D., & Su, F. (2024) · Frontiers in Nutrition · doi:10.3389/fnut.2024.1462789 · Cited by 8
H. Reinecke (Schriftführer), V. B., & Breithardt, G. (2006) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-006-0013-1 · Cited by 11
Aminotransferase-catalyzed asymmetric synthesis of benazepril intermediate
Hwang, B., Cha, M., Park, H., & Kim, B. (2011) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-011-0066-y · Cited by 8
What should be the blood pressure target for patients with chronic kidney disease?
Nicholas, S. B., Vaziri, N. D., & Norris, K. C. (2013) · Current Opinion in Cardiology · doi:10.1097/hco.0b013e32836208c2 · Cited by 8
Mineral Metabolites, Angiotensin II Inhibition and Outcomes in Advanced Chronic Kidney Disease
Jovanovich, A. J., Chonchol, M. B., Sobhi, A., Kendrick, J., Cheung, A. K., Kaufman, J. S., Smits, G., Jablonski, K., & and the HOST Investigators (2015) · American Journal of Nephrology · doi:10.1159/000441684 · Cited by 9
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Garrick, R. (2007) · Yearbook of Medicine · doi:10.1016/s0084-3873(08)70134-2 · Cited by 8
Holger Reinecke (Schriftführer), V. B., & Breithardt, G. (2006) · Clinical Research in Cardiology Supplements · doi:10.1007/s11789-006-0011-3 · Cited by 11
Sigmund, L. M., Seifert, T., Halder, R., Bergonzini, G., Johansson, M. J., Norrby, P., Jorner, K., & Kabeshov, M. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202510533 · Cited by 7
Modeling the renoprotective mechanisms of SGLT2 inhibition in hypertensive chronic kidney disease
Clemmer, J. S., Yen, T. E., & Obi, Y. (2023) · Physiological Reports · doi:10.14814/phy2.15836 · Cited by 10
“For the current study, we modeled the progression of hypertensive nephrosclerosis, the second leading cause of ESRD and mechanistically attributed to glomerular HTN (Costantino et al., 2021).”
BackgroundInfluentialTakeuchi, S., Kohno, T., Goda, A., Shiraishi, Y., Kitamura, M., Nagatomo, Y., Takei, M., Nomoto, M., Soejima, K., Kohsaka, S., et al. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132190 · Cited by 7
Prevention of Heart Failure in Patients with Chronic Kidney Disease
Raghban, A., Kirsop, J., & Tang, W. H. W. (2014) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-014-0428-z · Cited by 8
Prerenal Success in Chronic Kidney Disease
Hirsch, S. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.02.025 · Cited by 9
Kuo, K., Hung, S., Tseng, W., Liu, J., Lin, M.-H., Hsu, C.-C., & Tarng, D. (2017) · Oncotarget · doi:10.18632/oncotarget.19850 · Cited by 7
Hypertension Management in Patients with Chronic Kidney Disease in the Post-SPRINT Era
Jung, H. H. (2021) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2021.19.2.19 · Cited by 8
Tight Blood Pressure Control in Chronic Kidney Disease
Gentile, G., Mckinney, K., & Reboldi, G. (2022) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd9050139 · Cited by 8
“Similar findings come from another meta-analysis showing a 40% decrease in the risk of ESRD or the doubling of serum creatinine with ACEis compared to a placebo [48], and from a randomised trial enrolling non-diabetic patients with advanced CKD [49].”
ResultHaller, H. G., Bianchi, S., McCafferty, K., Arthur, S. P., Quinn, C. M., Budden, J., & Weir, M. R. (2022) · Kidney360 · doi:10.34067/kid.0001562022 · Cited by 8
“ARB 171 (41) 81 (39) MRA 31 (7) 18 (9)”
Chinnadurai, R., Rengarajan, S., Budden, J. J., Quinn, C. M., & Kalra, P. A. (2023) · American Journal of Nephrology · doi:10.1159/000533753 · Cited by 7
Antihypertensive and organ-protective effects of benazepril
Barrios, V., & Escobar, C. (2010) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.10.159 · Cited by 7
The Role of Na+-H+Exchanger Isoform 1 in Aldosterone-Induced Glomerulosclerosis in Vivo
Zhang, M., Chen, J., Liu, S., Li, Y., Lin, S., & Gu, Y. (2009) · Renal Failure · doi:10.3109/08860220903134571 · Cited by 7
“system (RAS) inhibition and aldosterone blockade has been associated with decreased proteinuria and glomerulosclerosis in patients with chronic kidney diseases and reduced renal damage.([20,21]) Terada et al.”
BackgroundDattolo, P. C. G., Gallo, P., Michelassi, S., Paudice, N., Cannavò, R., Romoli, E., Fani, F. M., Tsalouchos, A., Mehmetaj, A., Ferro, G., et al. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0290-9 · Cited by 8
“The incidence of adverse events, namely hyperkalemia and acute worsening of renal function, was similar between the active and placebo groups [11].”
BackgroundResultOnuigbo, M. A. C. (2016) · International Journal of Clinical Practice · doi:10.1111/ijcp.12916 · Cited by 7
The benefit of angiotensin AT1 receptor blockers for early treatment of hypertensive patients
Trimarco, B., Santoro, C., Pepe, M., & Galderisi, M. (2017) · Internal and Emergency Medicine · doi:10.1007/s11739-017-1713-x · Cited by 7
Antihypertensive therapy in nondiabetic chronic kidney disease: a review and update
Mesropian, P. J. D., Shaikh, G. G., Torres, E. C., Bilal, A., & Mathew, R. O. (2018) · Journal of the American Society of Hypertension · doi:10.1016/j.jash.2018.01.005 · Cited by 7
Thorp, M. L., Smith, D. H., Johnson, E. S., Vupputuri, S. X., Weiss, J. W., Petrik, A. F., Yang, X., Levey, A. S., Wasse, H., Muoneke, R., et al. (2012) · The Joint Commission Journal on Quality and Patient Safety · doi:10.1016/s1553-7250(12)38035-5 · Cited by 7
Slowing the progression of chronic kidney disease
Herrington, W. G., & Mason, P. D. (2009) · British Journal of Hospital Medicine · doi:10.12968/hmed.2009.70.11.45052 · Cited by 7
Safety of Benazepril in 400 Azotemic and 110 Non-Azotemic Client-Owned Cats (2001–2012)
Lavallee, J. O., Norsworthy, G. D., Huston, C. L., & Chew, D. J. (2017) · Journal of the American Animal Hospital Association · doi:10.5326/jaaha-ms-6577 · Cited by 8
Slowing Progression of Chronic Kidney Disease
Drawz, P. E., Hostetter, T. H., & Rosenberg, M. E. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815876-0.00057-7 · Cited by 10
WANG, A., Wang, Y.-P., WANG, G., Zhou, Z., & Yang, X. (2010) · Experimental and Therapeutic Medicine · doi:10.3892/etm_00000067 · Cited by 7
“Our previous research revealed that ACEI therapy significantly reduces the level of proteinuria and delays the rate of decline in renal function (17). however, patients with iE-associated glomerulonephritis were not included in this report. here, we used an adequate dosage of acEi and arBs in order…”
Self-citation(1997) · Annals of Pharmacotherapy · doi:10.1177/106002809703100720 · Cited by 7
Benazepril for Advanced Chronic Renal Insufficiency
Jaber, B. L., & Madias, N. E. (2006) · New England Journal of Medicine · doi:10.1056/nejmc060298 · Cited by 7
Chen, L., Yin, Y.-M., Luo, Q., Shao, J., Zhang, C., & Yan, S. (2025) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.5c01408 · Cited by 6
Mueller, Z. C., Ponzi, R. P., Sui, X. Z., Liu, P., & Hoveyda, A. H. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c09730 · Cited by 6
Elevations in serum creatinine with RAAS blockade: why isnʼt it a sign of kidney injury?
Ryan, M. J., & Tuttle, K. R. (2008) · Current Opinion in Internal Medicine · doi:10.1097/mci.0b013e32831daeff · Cited by 6
Netere, A. K., & Sendekie, A. K. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274495 · Cited by 10
A novel approach for the synthesis of (S)-tolvaptan and (S)-desmethyltolvaptan
Adarsh, D. R., Prashanth, S., Vinaykumar, A., & Reddy, B. V. S. (2024) · Tetrahedron Letters · doi:10.1016/j.tetlet.2024.155245 · Cited by 6
Liu, C., Chen, H., Liu, C., Fu, C., Zhang, H., Yang, H., Wang, P., Wang, F., Chen, S., & Ma, Q. (2014) · Journal of Nephrology · doi:10.1007/s40620-013-0011-6 · Cited by 6
Kitamura, M., Arai, H., Abe, S., Ota, Y., Muta, K., Furusu, A., Mukae, H., Kohno, S., & Nishino, T. (2020) · SAGE Open Medicine · doi:10.1177/2050312120973502 · Cited by 6
Antisense Oligonucleotide: A Potential Therapeutic Intervention for Chronic Kidney Disease
Li, Y., Tan, Y., Zhang, R., Wang, T., Na, N., Zheng, T., Veedu, R. N., & Chen, S. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2010004 · Cited by 7
When to initiate ACEI/ARB therapy in patients with type 1 and 2 diabetes
Lemley, K. V. (2010) · Pediatric Nephrology · doi:10.1007/s00467-010-1498-x · Cited by 7
“The risk of precipitating acute renal failure seems to be very low, even for patients with fairly advanced baseline renal insufficiency [ 96 ].”
BackgroundRenoprotective effects of benazepril: current perspective
Stompór, T. P., Napora, M., & Olszewski, A. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.55 · Cited by 6
Recent Advances in Palladium-Catalyzed Oxidative Cyclizations
Hershberger, J. C. (2019) · Current Organic Chemistry · doi:10.2174/1385272823666190429155004 · Cited by 6
Babu, G. V. S., Bhaskaran, A., Sridhar, B., Rao, T. V., & Prathima, P. S. (2021) · ChemistrySelect · doi:10.1002/slct.202003346 · Cited by 6
Pertschi, R., Miaskiewicz, S., Kern, N., Weibel, J., Pale, P., & Blanc, A. (2021) · Chem Catalysis · doi:10.1016/j.checat.2021.02.004 · Cited by 6
Pharmacological management of renal fibrotic disease
Gaedeke, J., Neumayer, H., & Peters, H. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.4.377 · Cited by 7
“As a recent study [67] suggests, even patients with a creatinine level of 3 – 5 mg/dl can be safely and effectively treated with benazepril.”
BackgroundBhandari, S., & Chadburn, M. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.09.014 · Cited by 6
Editorial: Preventing Cardio-renal Syndrome Rather than Treating It: Could Statins Play A Role?
Athyros, V. G., Katsiki, N., Τζιόμαλος, Κ., & Karagiannis, A. I. (2011) · The Open Cardiovascular Medicine Journal · doi:10.2174/1874192401105010226 · Cited by 7
Ahmed, A. A., Lu, F., Zhang, S., Raman, V. K., Patel, S. S., Morgan, C. J., Faselis, C., Lam, P. H., Fonarow, G. C., Heidenreich, P. A., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag076 · Cited by 6
Management of patients with heart failure and chronic kidney disease
Wu, L., Rodríguez, M., Hachem, K. E., Tang, W. H. W., & Krittanawong, C. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10415-9 · Cited by 6
“For patients with advanced CKD, initiation of benazepril was associated with a 23% reduction in the rate of progression of renal disease (ESRD, death, or doubling creatinine) in a RCT that enrolled patients with advanced CKD [38].”
Chen, I., Lin, Y.-H., Wu, V., Chen, J., & Wu, M. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1646969 · Cited by 5
Nephrotic Syndrome and Renin-angiotensin System: Pathophysiological Role and Therapeutic Potential
Silva, A. C. S. E., dos Anjos, A. A., de Paiva, I. T., Lima, G. L. S., Filha, R. D. S., Fróes, B. P. E., & Pinheiro, S. V. B. (2022) · Current Molecular Pharmacology · doi:10.2174/1874467215666220616152312 · Cited by 5
Wang, Y., Jiang, S., Zou, G., Zhuo, L., & Li, W. (2022) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1155/2022/9162427 · Cited by 5
“However, there are some stage 4 CKD patients benefiting from ACEI/ARB in trials, including the AIPRI [15], ESBARI [4], STOP-IgAN [16], and TESTING [17] trials.”
BackgroundIodine(III)‐Mediated Oxidation of Anilines to Construct Dibenzazepines**
White, C. M., Zorigt, N., Deng, T., & Driver, T. G. (2023) · Chemistry - A European Journal · doi:10.1002/chem.202301141 · Cited by 5
Management of Hypertension in the Outpatient Setting
Sica, D. A. (2008) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2008.05.002 · Cited by 5
Wang, P., Huang, Y., Lin, M., Chuang, P., & Hwang, S. (2012) · The Kaohsiung Journal of Medical Sciences · doi:10.1016/j.kjms.2012.04.004 · Cited by 7
“[23], which recruited patients with an Scr of up to 5 mg/dL.”
BackgroundCorticosteroids in Patients with IgA Nephropathy and Severe Chronic Renal Damage
Pozzi, C., Ferrario, F., Visciano, B., & Vecchio, L. D. (2012) · Case Reports in Nephrology · doi:10.1155/2012/180691 · Cited by 5
“ACE inhibitors have been proven effective in patients also with advanced CKD [5].”
BackgroundBloqueo del sistema renina-angiotensina-aldosterona en hipertensión arterial, diabetes y nefropatía
Marín, R., Navascués, R. A., & Fernández-Vega, F. (2008) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(08)76104-1 · Cited by 5
“Estudio ESPIRAL Fosinopril frente a amlodipino Mejor supervivencia renal con fosinopril Hou et al47, 2006 Benazepril frente a placebo Reducción del riesgo de alcanzar la IRC terminal Praga et al48, 2003.”
BackgroundIdentifying acute kidney injury in the community—a novel informatics approach
Xu, G., Player, P., Shepherd, D. J., & Brunskill, N. J. (2015) · Journal of Nephrology · doi:10.1007/s40620-015-0190-4 · Cited by 7
Pharmacotherapy of hypertension in patients with pre-dialysis chronic kidney disease
Loutradis, C., & Sarafidis, P. A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1726318 · Cited by 5
Potassium Derangements: A Pathophysiological Review, Diagnostic Approach, and Clinical Management
Sharif, S., & Tang, J. T. (2022) · Physiology · doi:10.5772/intechopen.103016 · Cited by 7
Zhang, X., Wang, X., Jiao, C., Zhao, J., Liu, X., & Zhang, G. (2022) · Organic Chemistry Frontiers · doi:10.1039/d2qo01147f · Cited by 5
Self-citationA nationwide survey of MYH9-related disease in Japan
Shirai, Y., Miura, K., Hamada, R., Ishikura, K., Kunishima, S., & Hattori, M. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02404-3 · Cited by 5
“Based on the results of clinical trials demonstrating the effectiveness of RAS inhibitors in delaying the progression of chronic kidney disease, major clinical practice guidelines recommend the use of RAS inhibitors for patients with chronic kidney disease [18–20].”
Ito, M., Saka, Y., Kuroki, Y., Yasuda, K., Tsujimoto, H., Tsujimoto, Y., Yuasa, H., Ryuzaki, M., Ito, Y., & Nakamoto, H. (2019) · Renal Replacement Therapy · doi:10.1186/s41100-019-0238-3 · Cited by 5
Danyliuk, I. Y., Vaskevych, R. I., Vaskevych, A. I., Suikov, S. Y., Rusanov, E. B., Чорноус, В. А., & Vovk, M. V. (2019) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.3779 · Cited by 5
The Xanthate Route to Benzazepinones and Their Aza Congeners
Zard, S. Z., & Quiclet‐Sire, B. (2022) · Heterocycles · doi:10.3987/rev-22-sr(r)9 · Cited by 5
Pecoits‐Filho, R., McCullough, K. P., Muenz, D. G., Quinn, C. M., Budden, J., Golden, J., de Arellano, A. R., Tillmann, F.-P., Duttlinger, J., Cálice-Silva, V., et al. (2022) · Clinical Kidney Journal · doi:10.1093/ckj/sfac209 · Cited by 5
THE IMPORTANCE OF RENIN‐ANGIOTENSIN BLOCKADE IN PATIENTS WITH CARDIO‐RENAL DISEASE
Benavente, D., Chue, C. D., & Ferro, C. J. (2010) · Journal of Renal Care · doi:10.1111/j.1755-6686.2010.00166.x · Cited by 6
Leitliniengerechte Differenzialtherapie der Hypertonie
Rahn, K. H. (2009) · Der Internist · doi:10.1007/s00108-008-2292-8 · Cited by 5
End-stage chronic heart failure
Leibundgut, G., & Rocca, H. B. (2007) · Swiss Medical Weekly · doi:10.4414/smw.2007.11673 · Cited by 7
“Even in advanced renal failure, ACE-inhibition is beneficial [ 9 ].”
BackgroundShould we shift toward higher blood pressure targets in patients with chronic kidney disease
Gentile, G., & Strippoli, G. F. (2011) · Journal of Nephrology · doi:10.5301/jn.5000052 · Cited by 5
End-Stage Renal Disease and Sudden Cardiac Death
Sakhuja, R., Shah, A. J., Hiremath, S. S., & Thakur, R. K. (2009) · Cardiac Electrophysiology Clinics · doi:10.1016/j.ccep.2009.08.006 · Cited by 5
Gatault, P., Al-Najjar, A., Barbet, C., Roland, M., Laouad, I., Büchler, M., Marliere, J.-F., Métais, P. E., Clément, A., Nivet, H., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e31823015e4 · Cited by 5
“For instance, results of a recent clinical trial described the incidence of the primary endpoint (DSC, ESRD, or death) in nontransplanted patients with different baseline renal function (20).”
BackgroundGarg, A. X., Greene, T., & Levin, N. W. (2007) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfm712 · Cited by 5
“Examples of recent positive trials in nephrology include mycophenolate for active lupus nephritis [8], angiotensin-converting enzyme inhibitors in advanced chronic kidney disease [9], combination ACE inhibitor and angiotensin-receptor blocker therapy in non-diabetic renal disease [10], education for patients with chro…”
BackgroundDiagnostic, facteurs de risque et traitement de l'insuffisance rénale chronique de l'adulte
Krummel, T., Bazin, D., Faller, A.-L., & Hannedouche, T. P. (2011) · Encyclopédie médico-chirurgicale. Néphrologie · doi:10.1016/s1762-0945(11)38514-2 · Cited by 6
HIGH RESOLUTION RP-HPLC METHOD FOR THE DETERMINATION OF HYPERTENSIVE DRUG PRODUCTS
Prasad, K. R. S., & Mallu, U. R. (2013) · Cited by 5
Travagim, D. S. A. (2012) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.22.2012.tde-05112012-162300 · Cited by 5
Samuel, S., Craver, K., Miller, C. C., Pelsue, B., Gonzalez, C., Allison, T. A., Gulbis, B. E., Choi, H. A., & Kim, S. (2024) · American Journal of Hypertension · doi:10.1093/ajh/hpae033 · Cited by 4
Nielsen, S. K., Lamberts, M., Nouhravesh, N., Jensen, M. H., Strange, J. E., Gislason, G., McGettigan, P., & Holt, A. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132137 · Cited by 4
Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole
Yee, J. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.001 · Cited by 4
Gbadamosi, I. T., Opatola, D. G., Oyagbemi, A. A., Ajibade, T. O., Bolaji‐Alabi, F. B., Omóbòwálé, T. O., Saba, A. B., Adedapo, A. A., Yakubu, M. A., & Oguntibeju, O. O. (2020) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2020-0065 · Cited by 4
Hu, L., Zhang, J., Li, M., Feng, Y., & Lu, F. (2024) · RSC Advances · doi:10.1039/d4ra01914h · Cited by 4
Correa-Rotter, R., Wheeler, D. C., & McEwan, P. C. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02950-6 · Cited by 4
“Further REIN [53, 54]; Guang-zhou [55]; DAPA-CKD [5] analyses may be required to consider the effect of increased cardiovascular or other causes of mortality in a population which experiences a substantial delay to KRT initiation, even with the demonstrated clinical benefit of SGLT2 inhibitors in…”
Background
Metadata
- Authors
- Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., & Geng, R. W.
- Affiliations
- Nanfang Hospital (CN)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-01-12
- Volume
- 354
- Issue
- 2
- Pages
- 131-140
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2063210769
- Cited by
- 710
- References
- 22
- Citations by year
- 2026: 22 · 2025: 37 · 2024: 31 · 2023: 42 · 2022: 42 · 2021: 43 · 2020: 31 · 2019: 43 · 2018: 28 · 2017: 23 · 2016: 29 · 2015: 24 · 2014: 39 · 2013: 30 · 2012: 39
- FWCI
- 31.05
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- benazepril, ACE inhibitors, end-stage renal disease, renal protection, proteinuria, renal function decline, serum creatinine doubling, non-diabetic patients, adverse events
- MeSH terms
- Adult, Aged, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Benzazepines, Blood Pressure, China, Creatinine, Double-Blind Method, Female, Humans, Kidney Failure, Chronic, Male, Middle Aged, Proteinuria, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.